Biogen (BIIB) Revenue — Quarter Ended Dec 31, 2024
Revenue for the quarter was essentially flat compared to the prior quarter. Compared to the same quarter last year, revenue showed a modest increase.
Key takeaway
Quarter ended Dec 31, 2024 · FY2024 Q4
Revenue for the quarter was essentially flat compared to the prior quarter. Compared to the same quarter last year, revenue showed a modest increase.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$2.5B
Revenue reported for this quarter.
Quarter-over-quarter
-0.5%
Change from the immediately preceding quarter.
Year-over-year
+2.9%
Change from the comparable year-ago quarter.
Trailing four quarters
$9.7B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Mar 31, 2024 | $2.3B | -7.0% |
| Jun 30, 2024 | $2.5B | +0.4% |
| Sep 30, 2024 | $2.5B | -2.5% |
| Dec 31, 2024 | $2.5B | +2.9% |
Revenue performance
The reported revenue remained stable sequentially, reflecting consistent performance. On a year-over-year basis, the revenue improved, indicating growth from the same period a year earlier.
Quarterly comparison
Compared to the immediately preceding quarter, revenue was nearly unchanged. Relative to the same quarter one year ago, revenue was higher, marking a positive annual comparison.
What to watch
Monitor the impact of the HI-Bio acquisition on future revenue streams, as the deal closed in the middle of the year.